Treatment of COVID-19: implications for antimicrobial resistance in Africa.

Autor: Iwu CJ; Department of Nursing and Midwifery, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa., Jordan P; Department of Nursing and Midwifery, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa., Jaja IF; Department of Livestock and Pasture Sciences, Faculty of Science and Agriculture, University of Fort Hare, Alice 5700, South Africa., Iwu CD; School of Health Systems and Public Health, Faculty of Health Sciences, University of Pretoria, Pretoria 0001, South Africa., Wiysonge CS; Cochrane South Africa, South African Medical Research Council, Cape Town, South Africa.; Division of Epidemiology and Biostatistics, Stellenbosch University, Cape Town, South Africa.; School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
Jazyk: angličtina
Zdroj: The Pan African medical journal [Pan Afr Med J] 2020 Jul 20; Vol. 35 (Suppl 2), pp. 119. Date of Electronic Publication: 2020 Jul 20 (Print Publication: 2020).
DOI: 10.11604/pamj.supp.2020.35.23713
Abstrakt: There is currently no approved pharmaceutical product for the treatment of COVID-19. However, antibiotics are currently being used for the management of COVID-19 patients in many settings either treat to co-infections or for the treatment of COVID-19 itself. In this commentary, we highlight that the increased rates of antimicrobial prescribing for COVID-19 patients could further worsen the burden of antimicrobial resistance (AMR). We also highlight that though AMR is a global threat, Africa tends to suffer most from the consequences. We, therefore, call on African countries not to lose sight of the possible implications of the treatment of COVID-19 on AMR and a need to redouble efforts towards the fight against AMR while dealing with the pandemic.
Competing Interests: The authors declare no competing interests.
(©Chinwe Juliana Iwu et al.)
Databáze: MEDLINE